

## HR 3678

### Preserving Access to Orphan Drugs Act of 2015

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Oct 1, 2015

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 2, 2015)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/3678>

## Sponsor

**Name:** Rep. Kelly, Mike [R-PA-3]

**Party:** Republican • **State:** PA • **Chamber:** House

## Cosponsors (10 total)

| Cosponsor                         | Party / State | Role | Date Joined |
|-----------------------------------|---------------|------|-------------|
| Rep. Black, Diane [R-TN-6]        | R · TN        |      | Oct 1, 2015 |
| Rep. Holding, George [R-NC-13]    | R · NC        |      | Oct 1, 2015 |
| Rep. Jenkins, Lynn [R-KS-2]       | R · KS        |      | Oct 1, 2015 |
| Rep. Marchant, Kenny [R-TX-24]    | R · TX        |      | Oct 1, 2015 |
| Rep. Neal, Richard E. [D-MA-1]    | D · MA        |      | Oct 1, 2015 |
| Rep. Nunes, Devin [R-CA-22]       | R · CA        |      | Oct 1, 2015 |
| Rep. Rangel, Charles B. [D-NY-13] | D · NY        |      | Oct 1, 2015 |
| Rep. Tiberi, Patrick J. [R-OH-12] | R · OH        |      | Oct 1, 2015 |
| Rep. Kinzinger, Adam [R-IL-16]    | R · IL        |      | Oct 6, 2015 |
| Rep. Pompeo, Mike [R-KS-4]        | R · KS        |      | Oct 6, 2015 |

## Committee Activity

| Committee                     | Chamber | Activity    | Date        |
|-------------------------------|---------|-------------|-------------|
| Energy and Commerce Committee | House   | Referred to | Oct 2, 2015 |
| Ways and Means Committee      | House   | Referred to | Oct 1, 2015 |

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

No related bills are listed.

## Preserving Access to Orphan Drugs Act of 2015

This bill amends the Patient Protection and Affordable Care Act to expand the definition of orphan drug for purposes of the annual fee paid by brand name prescription drug manufacturers and importers to include medications for rare conditions that were, prior to 2011, approved or in clinical trials. (Drug manufacturers and importers pay an annual fee based on their sales of brand name prescription drugs, excluding sales of orphan drugs.) Currently, only medications for rare conditions for which a tax credit for clinical trials was allowed are considered orphan drugs.

This Act applies to fees paid after 2014.

### **Actions Timeline**

---

- **Oct 2, 2015:** Referred to the Subcommittee on Health.
- **Oct 1, 2015:** Introduced in House
- **Oct 1, 2015:** Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 1, 2015:** Referred to the Subcommittee on Health.